Ask the Expert: Navigating ALK+ Cancer with Dr. Geoffrey Liu

This webinar covers the questions that matter most to the ALK-positive community in Canada, including the latest research updates for ALK-positive patients, treatment paths and options such as targeted therapies and chemotherapy, how clinical trials come to Canada, and where access to neladalkib stands as Nuvalent works to bring it through approvals. 

Why this matters: 

Navigating ALK-positive NSCLC means making informed decisions about treatments, trials, and care — but reliable, Canada-specific information can be hard to find. This session gives patients, caregivers, and healthcare professionals direct access to one of the country’s leading ALK experts, with practical guidance grounded in the latest evidence.

What you’ll learn:

• How Nuvalent is ensuring Canadians will have access to neladalkib as it continues through trial and approvals
• How trials come to Canada and where we are today
• Access to treatments in Canada
• Treatment paths including chemotherapy 
• When and how dose reductions are considered
• Research updates relevant for ALK+ patients
• Managing side effects
• And more!

Watch this session for real, practical and patient‑focused information from medical oncologist Dr. Geoffrey Liu (Princess Margaret Cancer Centre, University of Toronto).

About Dr. Geoffrey Liu
Dr. Geoffrey Liu is a Medical Oncologist and the M. Qasim Choski Chair in Lung Cancer Translational Research at Princess Margaret Cancer Centre, and Professor at the University of Toronto. He has opened 19 ALK and 6 ROS1 clinical trials and has over 500 peer-reviewed publications in lung cancer research.